Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
Clinical and genetic spectrum of L-dopa responsive dystonia: insights from seven Egyptian cases.
СтатьяКлинический случайНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Almenabawy Nihal, Amer Fawzia, Selim Laila, Hassaan Hebatallah M
Аннотация
BACKGROUND: Dopa-responsive dystonia (DRD) encompasses a group of treatable movement disorders with significant clinical and genetic heterogeneity. Despite being treatable, DRD is often misdiagnosed, leading to delays in therapy.
METHODS: This retrospective study aims to describe the clinical and genetic features of seven Egyptian patients from four unrelated families with confirmed DRD. Medical records were reviewed to document clinical data, neuroimaging, and genetic testing.
RESULTS: We identified six patients with Tyrosine hydroxylase-deficient DRD and one with GTP cyclohydrolase 1 deficiency. The age at onset of initial symptoms ranged from 0.6 to 1.5 years. Universal clinical features included motor delay, weakness, and delayed speech and language development. Neuroimaging findings showed periventricular demyelination in two patients and brain atrophic changes in one. We identified two previously reported variants in the TH gene (c.-70G > A and c.938G > T) and one novel variant in the GCH1 gene (c.343 + 1G > A). All patients, except one, showed a complete response to L-dopa therapy within the first six months of treatment.
CONCLUSION: This first Egyptian cohort highlights DRD as a treatable yet underdiagnosed cause of dystonia in the Middle East. We report a novel GCH1 variant and TH-related type A phenotypes, underscoring the importance of early genetic diagnosis and levodopa therapy.
METHODS: This retrospective study aims to describe the clinical and genetic features of seven Egyptian patients from four unrelated families with confirmed DRD. Medical records were reviewed to document clinical data, neuroimaging, and genetic testing.
RESULTS: We identified six patients with Tyrosine hydroxylase-deficient DRD and one with GTP cyclohydrolase 1 deficiency. The age at onset of initial symptoms ranged from 0.6 to 1.5 years. Universal clinical features included motor delay, weakness, and delayed speech and language development. Neuroimaging findings showed periventricular demyelination in two patients and brain atrophic changes in one. We identified two previously reported variants in the TH gene (c.-70G > A and c.938G > T) and one novel variant in the GCH1 gene (c.343 + 1G > A). All patients, except one, showed a complete response to L-dopa therapy within the first six months of treatment.
CONCLUSION: This first Egyptian cohort highlights DRD as a treatable yet underdiagnosed cause of dystonia in the Middle East. We report a novel GCH1 variant and TH-related type A phenotypes, underscoring the importance of early genetic diagnosis and levodopa therapy.